Huntington's disease (HD) is a progressive, autosomal dominant neurodegenerative disorder caused by a CAG trinucleotide repeat expansion (≥36 repeats) in the HTT gene on chromosome 4p16.3. [1-2] It is characterized by a triad of motor dysfunction (chorea), cognitive decline, and psychiatric disturbances, with a mean onset around age 35–45 and median survival of 15–20 years after diagnosis. [2-3] Acute presentations to the ED are common and typically reflect intercurrent complications (infections, aspiration, falls) or psychiatric crises (suicidality, psychosis, agitation) rather than the disease itself, since HD progression is usually slow. [4]
1. History
- Known HD diagnosis vs. new presentation: Confirm genetic testing status, CAG repeat length, disease stage (Shoulson-Fahn Stage I–V), and baseline functional capacity [5]
- Acute change from baseline: HD progression is slow; acute deterioration should prompt a search for intercurrent illness — infections (UTI, pneumonia), constipation, urinary retention, GERD, poor dentition, medication changes, or dehydration [4]
- Symptom characterization: Onset, duration, and tempo of worsening chorea, new rigidity, gait instability, falls, dysphagia, or weight loss
- Psychiatric symptoms: Depression, suicidal ideation/plan/intent, agitation, irritability, psychosis (delusions, hallucinations), disinhibition, apathy [3][5]
- Medication history: Current VMAT2 inhibitors (tetrabenazine, deutetrabenazine, valbenazine), antipsychotics, antidepressants — recent dose changes, missed doses, or new medications [6-7]
- Swallowing difficulties: Choking episodes, coughing with meals, food avoidance, recent aspiration events [8-9]
- Important negatives: Fever, urinary symptoms, bowel changes, recent trauma/falls, substance use
2. Alarm Features
- Suicidal ideation or attempt: HD patients have a 2–7× higher suicide risk than the general population; suicide is the third leading cause of death in HD (6.6% of deaths). Critical periods include the pre-manifest/early symptomatic stage and periods of functional decline [3][10-12]
- Aspiration pneumonia: Leading cause of death in HD; signs include fever, tachypnea, hypoxia, productive cough in a patient with known dysphagia [3][13]
- Neuroleptic malignant syndrome (NMS): Rigidity, hyperthermia, autonomic instability, altered mental status — particularly with antipsychotic or tetrabenazine use [7]
- Acute psychosis with violence/aggression: Reported in ~39% of psychiatric admissions in HD [14]
- Severe chorea with exhaustion, dehydration, or rhabdomyolysis: Continuous involuntary movements can lead to metabolic derangement
- New focal neurological deficit: Should raise concern for stroke or subdural hematoma (falls are common)
- Rapid cognitive decline: Consider delirium from infection, metabolic derangement, or medication toxicity rather than HD progression alone
3. Medications
Chorea management (FDA-approved VMAT2 inhibitors)
- Tetrabenazine: Start 12.5 mg daily, titrate by 12.5 mg/week; max 50 mg/day (CYP2D6 poor metabolizers) or 100 mg/day (extensive metabolizers). Boxed warning: depression and suicidality [7]
- Deutetrabenazine (Austedo): Better tolerability; common AEs include somnolence, dry mouth, diarrhea; similar boxed warning for depression/suicidality [6][15]
- Valbenazine (Ingrezza): Once-daily dosing, favorable tolerability profile [6][15-16]
Psychiatric symptoms
- Atypical antipsychotics (olanzapine, risperidone, aripiprazole): Dual benefit for chorea and psychiatric symptoms; olanzapine showed improvement in chorea, behavior, and irritability in the Neuro-HD trial [17-19]
- SSRIs/SNRIs: First-line for depression; monitor closely for suicidality
- Benzodiazepines: Adjunctive for anxiety, agitation, and acute chorea [5]
- Valproic acid: For myoclonic hyperkinesia [5]
Contraindicated/caution
- L-dopa-containing compounds: May worsen chorea [5]
- MAOIs: Contraindicated with tetrabenazine (minimum 14-day washout) [7]
- Reserpine: At least 20 days washout before starting tetrabenazine [7]
- QTc-prolonging drugs: Use caution with VMAT2 inhibitors, particularly tetrabenazine [6]
- Strong CYP2D6 inhibitors (fluoxetine, paroxetine): Require dose reduction of tetrabenazine (max 50 mg/day, max single dose 25 mg) [7]
4. Diet
- Dysphagia management: Modified texture diets (pureed, thickened liquids) based on speech-language pathology assessment; supervision during meals is critical [9][20]
- High-calorie needs: HD patients have significantly increased caloric requirements due to continuous involuntary movements and hypermetabolism; weight loss is common and progressive [5][21]
- Aspiration precautions: Upright positioning during and after meals, small bolus sizes, avoidance of mixed-consistency foods
- Hydration: Dehydration is common due to dysphagia and increased metabolic demands; IV fluids often needed acutely
- Alcohol avoidance: Recommended due to fall risk, cognitive impairment, and medication interactions [5]
5. Review of Systems
- Neurological: Chorea severity, dystonia, rigidity, gait instability, falls, dysarthria, dysphagia, eye movement abnormalities
- Psychiatric: Depression, anxiety, irritability, apathy, psychosis, suicidal ideation, aggression, disinhibition, obsessive-compulsive behaviors [3][5]
- GI: Constipation (very common), GERD, nausea, weight loss, choking episodes [4]
- GU: Urinary retention, incontinence [4]
- Pulmonary: Cough, dyspnea, aspiration symptoms
- MSK: Myalgias, injuries from falls or involuntary movements
- Constitutional: Fever, fatigue, unintentional weight loss
6. Collateral History and Family History
- Family history: HD is autosomal dominant with complete penetrance at ≥40 CAG repeats; ~8% of patients have no known family history. Inquire about affected parents, siblings, and their disease course [1][22]
- Collateral from caregivers: Essential for assessing baseline function, recent behavioral changes, medication adherence, fall frequency, and nutritional intake — patients often have impaired insight [5]
- Genetic testing status: Confirm whether the patient has had confirmatory genetic testing (CAG repeat length)
- Advance directives: Particularly important in moderate-to-advanced disease; inquire about goals of care, code status, and healthcare proxy
- Social context: Living situation, caregiver burden, access to HD specialty care, financial/insurance status (80.6% of hospitalized HD patients have Medicare/Medicaid) [13]
7. Risk Factors
- Genetic: Autosomal dominant; longer CAG repeats correlate with earlier onset (≥55 repeats → juvenile HD) [1-2]
- Suicide risk factors: Depression (65% lifetime prevalence), prior suicide attempts, anxiety, irritability, psychosis, apathy, loss of functional independence, early symptomatic stage [10-11][23-24]
- Aspiration risk: Disease stage (100% of advanced-stage patients have dysphagia), worsening motor symptoms, bradykinesia, lingual protrusion impairment [8][25]
- Falls: Gait ataxia, postural instability, chorea, cognitive impairment
- Malnutrition: Age ≥65, disease severity, prolonged oral phase, impaired swallowing safety [21]
8. Differential Diagnosis
When HD is not yet confirmed, the differential for chorea + cognitive decline + psychiatric symptoms includes:
- Tardive dyskinesia: Antipsychotic exposure history; typically orobuccal predominance [3][26]
- Wilson disease: Younger patients; Kayser-Fleischer rings, low ceruloplasmin, hepatic dysfunction [5][22]
- Sydenham chorea: Post-streptococcal; typically children/adolescents [27-28]
- HD phenocopies: HDL2 (especially in patients of African descent), SCA17, C9orf72 expansions, neuroacanthocytosis [5][26][29]
- Autoimmune chorea: SLE, antiphospholipid syndrome, anti-NMDAR encephalitis, anti-IgLON5 [28-29]
- Drug-induced chorea: Levodopa, stimulants, oral contraceptives, anticonvulsants [26][28]
- Vascular hemichorea/hemiballism: Acute onset, unilateral, contralateral subthalamic or basal ganglia lesion [28]
- Thyrotoxicosis: Tremor, weight loss, tachycardia; check TSH [5]
- Creutzfeldt-Jakob disease: Rapid progression, myoclonus, characteristic MRI/EEG findings [26]
- Neuroacanthocytosis: Areflexia, elevated CK, acanthocytes on peripheral smear, seizures [22][26]
9. Past Medical History
- Prior psychiatric hospitalizations (11.1% of HD patients in one cohort had at least one psychiatric admission) [14]
- Previous suicide attempts or ideation
- History of falls, fractures, head injuries
- Aspiration pneumonia episodes
- Nutritional deficiencies, weight trajectory
- Medication trials and responses (VMAT2 inhibitors, antipsychotics, antidepressants)
- Comorbid conditions: diabetes, cardiovascular disease, decubitus ulcers
- Surgical history (PEG tube placement, tracheostomy in advanced disease)
10. Physical Exam
- Vitals: Fever (infection), tachycardia (dehydration, sepsis, NMS), hypotension (dehydration), tachypnea (aspiration pneumonia), SpO₂
- Neurological:
- Chorea assessment: Observe for involuntary, irregular, purposeless movements flowing from one body part to another; quantify using the UHDRS Total Maximal Chorea (TMC) score (0–28) [6]
- Dystonia and rigidity: Particularly in advanced disease or juvenile HD [3][5]
- Oculomotor exam: Impaired saccade initiation, slow/hypometric saccades, gaze fixation difficulty (present in up to 75%) [5]
- Motor impersistence: Inability to maintain tongue protrusion or grip ("milkmaid's grip") — characteristic of HD [22]
- Gait: Ataxic, wide-based, staggering (can mimic intoxication) [5]
- Dysarthria: Assess speech intelligibility
- Reflexes: Hyperreflexia (90% early), clonus and extensor plantar responses (late) [5]
- Psychiatric: Mental status exam, affect, thought content (delusions, hallucinations), suicidal ideation assessment (C-SSRS recommended) [30]
- Oral exam: Dentition, oral hygiene (poor dentition is a common cause of acute deterioration) [4]
- Skin: Decubitus ulcers in advanced/immobile patients
- Abdominal: Distension, bowel sounds (constipation is very common)
11. Lab Studies
- CBC: Infection workup; acanthocytes on peripheral smear if neuroacanthocytosis suspected [22]
- BMP/CMP: Electrolytes, renal function (dehydration, rhabdomyolysis), glucose (hyperglycemia can cause chorea), hepatic function
- CK: If prolonged severe chorea, immobility, or suspected rhabdomyolysis
- Urinalysis + culture: UTI is a common cause of acute deterioration [13]
- Blood cultures: If febrile or sepsis suspected
- TSH: Rule out thyrotoxicosis as cause of chorea [5]
- Ceruloplasmin, serum copper: If Wilson disease is in the differential (young patients, no family history) [5]
- Procalcitonin/lactate: If sepsis is suspected
- Drug levels: Antiepileptic drug levels if applicable; toxicology screen if substance use suspected
- CYP2D6 genotyping: Required before exceeding tetrabenazine 50 mg/day [7]
To rule out dangerous conditions
- ANA, antiphospholipid antibodies, anti-NMDAR antibodies if autoimmune chorea suspected [29]
- HTT genetic testing (CAG repeat analysis) if HD not yet confirmed [1]
12. Imaging
- CT head (without contrast): First-line in the ED for acute mental status change, new focal deficit, or head trauma from falls — look for subdural hematoma, stroke
- MRI brain: Gold standard; shows characteristic caudate atrophy with enlarged frontal horns of lateral ventricles ("box-car" ventricles), generalized cortical atrophy. Not typically needed acutely unless stroke or other structural pathology is suspected [2][5]
- Chest X-ray: If aspiration pneumonia suspected (fever, cough, hypoxia, dysphagia)
- CT chest: If CXR is equivocal and high clinical suspicion for aspiration
- Imaging is unnecessary: For routine HD follow-up in the ED if the presentation is consistent with known disease trajectory
13. Special Tests
- Unified Huntington's Disease Rating Scale (UHDRS): Standardized assessment of motor, cognitive, behavioral, and functional capacity — useful for documenting baseline and tracking change [5][31]
- Total Maximal Chorea (TMC) score: Subscale of UHDRS (0–28); used to quantify chorea severity [6]
- Columbia Suicide Severity Rating Scale (C-SSRS): Recommended for structured suicide risk assessment in HD [30]
- Fiberoptic Endoscopic Evaluation of Swallowing (FEES) or Videofluoroscopic Swallowing Study (VFSS): Gold standard for dysphagia assessment; FEES is feasible in HD patients across all stages [8-9][32]
- Bedside Swallowing Assessment Scale (BSAS): Clinical screening tool for dysphagia [25]
- Montreal Cognitive Assessment (MoCA) or MMSE: Cognitive screening
- Genetic testing: CAG repeat analysis of HTT gene confirms diagnosis; ≥36 repeats diagnostic, ≥40 fully penetrant [1-2]
14. ECG
- Indications: Obtain ECG in patients on VMAT2 inhibitors (especially tetrabenazine), antipsychotics, or other QTc-prolonging medications [6-7]
- QTc prolongation: VMAT2 inhibitors, particularly tetrabenazine, are associated with mild QTc prolongation; avoid combining with other QTc-prolonging agents [6]
- Electrolyte-related arrhythmias: Hyperkalemia from rhabdomyolysis; hypokalemia/hypomagnesemia from malnutrition or dehydration
- Baseline ECG: Recommended before initiating or adjusting VMAT2 inhibitors or antipsychotics
15. Assessment
- Acute deterioration in a known HD patient most commonly reflects an intercurrent problem (infection, constipation, urinary retention, medication change, dehydration, poor dentition) rather than disease progression, which is gradual [4]
- Psychiatric crises are the second most common reason for HD hospitalization (21.5%), with suicidal ideation/attempt (57.6%), psychosis (39.4%), and aggression (36.4%) being the leading indications for psychiatric admission [13-14]
- Aspiration pneumonia is the most common reason for medical admission (22%) and the leading cause of death [1][13]
- Severity stratification: Use disease stage (Shoulson-Fahn I–V), functional capacity (UHDRS Total Functional Capacity), and the specific acute presentation to guide disposition
- Atypical presentations: Juvenile HD (onset <20 years) presents with bradykinesia, rigidity, dystonia, and seizures rather than chorea. Late-onset HD (>50 years) may have a more benign course [3][5][33]
16. Treatment Plan
Initial stabilization
- ABCs; airway protection if severe dysphagia or aspiration
- IV fluid resuscitation for dehydration (common due to dysphagia and hypermetabolism)
- Treat underlying cause of acute deterioration (antibiotics for infection, bowel regimen for constipation, catheterization for urinary retention) [4]
Acute chorea exacerbation
- Ensure current VMAT2 inhibitor or antipsychotic is being taken; resume if missed doses
- Benzodiazepines (lorazepam 1–2 mg IV/IM) for acute severe chorea or agitation [5]
- Avoid L-dopa-containing compounds [5]
Acute agitation/aggression
- De-escalation first; then oral olanzapine (5–10 mg) or risperidone (1–2 mg) preferred given dual benefit for chorea and psychiatric symptoms [17][19][34]
- If parenteral needed: IM olanzapine 10 mg, IM haloperidol 5 mg + lorazepam 2 mg, or IM midazolam 5 mg [34-35]
- Avoid combining IM olanzapine with IM benzodiazepines (risk of respiratory depression)
Acute psychosis
- Atypical antipsychotics are first-line: olanzapine and risperidone most commonly used; aripiprazole is an alternative [18-19]
- ECT is safe and effective for refractory psychosis in HD [18]
Suicidality
- Immediate psychiatric evaluation; 1:1 observation
- Assess and treat underlying depression (SSRIs); consider whether VMAT2 inhibitors are contributing [7]
- Tetrabenazine is contraindicated in actively suicidal patients or those with untreated/inadequately treated depression [7]
Aspiration pneumonia
- Antibiotics covering aspiration flora (ampicillin-sulbactam, or clindamycin + fluoroquinolone)
- NPO until swallowing assessment; speech-language pathology consult
- Supplemental oxygen, respiratory support as needed
17. Disposition
Admission criteria
- Aspiration pneumonia or respiratory compromise
- Active suicidal ideation or attempt (psychiatric admission)
- Acute psychosis with aggression or inability to care for self
- Severe dehydration, rhabdomyolysis, or electrolyte derangements
- Sepsis or serious intercurrent infection
- NMS or suspected NMS
- Inability to maintain oral intake
Observation indications
- Mild dehydration responding to IV fluids
- Medication adjustment requiring monitoring (e.g., VMAT2 inhibitor titration)
- Fall with minor injury requiring serial neurological exams
Discharge criteria
- Acute issue resolved and patient at baseline functional status
- Safe disposition environment with adequate caregiver support
- Medications reconciled and refilled
- Follow-up arranged
Key disposition pearl: In a US hospitalization study, 60% of HD patients admitted to the hospital were discharged to long-term care facilities rather than home, and 54.4% of all admissions resulted in LTCF placement — hospitalization often marks a transition point in care. [13]
Specialist consultation triggers
- Neurology (HD specialist): New diagnosis, medication adjustment, disease progression
- Psychiatry: Suicidality, psychosis, refractory behavioral symptoms
- Speech-language pathology: Dysphagia assessment
- Palliative care: Advanced disease, goals-of-care discussions
- Genetics: New diagnosis, family counseling, predictive testing for at-risk relatives
18. Follow Up / Return Precautions
- Follow-up timing: Neurology within 1–2 weeks after ED visit or discharge; psychiatry within 1 week if psychiatric symptoms were the presenting complaint; PCP within 3–5 days
- Return precautions:
- Worsening or new suicidal thoughts or self-harm behavior
- Fever, worsening cough, or difficulty breathing (aspiration)
- Inability to eat or drink, choking episodes
- New or worsening confusion, agitation, or hallucinations
- Falls with head injury or inability to ambulate
- Muscle rigidity with fever (concern for NMS)
- Patient/caregiver counseling:
- Medication adherence is critical; do not abruptly stop VMAT2 inhibitors or antipsychotics
- Ensure safe home environment (fall prevention, supervised meals)
- Connect with HD support organizations (HDSA) for resources and caregiver support [5]
- Expected course: HD is slowly progressive; acute setbacks from intercurrent illness are common but often reversible with appropriate treatment. Functional decline over years is expected, and advance care planning should be revisited regularly [4-5]
References
1. Huntington's Disease: A Clinical Review. — Roos RA. Orphanet Journal of Rare Diseases. 2010.
2. Huntington's Disease: From Molecular Pathogenesis to Clinical Treatment. — Ross CA, Tabrizi SJ. The Lancet. Neurology. 2011.
3. Diagnostic and Statistical Manual of Mental Disorders. — Dilip V. Jeste, Jeffrey A. Lieberman, David Fassler, et al American Psychiatric Association (2022). 2022.
4. Huntington's Disease: A Clinical Primer for Acute and General Physicians. — Massey TH, McLauchlan DJ. Clinical Medicine. 2024.
5. Huntington Disease. — Caron NS, Wright GEB, Hayden MR GeneReviews® [Internet]. 2020.
6. Vesicular Monoamine Transport Inhibitors: Current Uses and Future Directions. — Rosenthal LS, Farag M, Aziz NA, Bang J. Lancet. 2025.
7. FDA Drug Label. — Updated date: 2019-11-29. Food and Drug Administration.
8. Fiberoptic Endoscopic Evaluation of Swallowing in Early-to-Advanced Stage Huntington's Disease. — Schindler A, Pizzorni N, Sassone J, et al. Scientific Reports. 2020.
9. Management of Dysphagia in Huntington's Disease: A Descriptive Review. — Pizzorni N, Pirola F, Ciammola A, Schindler A. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2020.
10. Suicidal Ideation and Behavior in Huntington's Disease: Systematic Review and Recommendations. — Kachian ZR, Cohen-Zimerman S, Bega D, Gordon B, Grafman J. Journal of Affective Disorders. 2019.
11. Risk Factors and Interventions for Suicide in Huntington's Disease-a Systematic Review. — Grimaldi A, Veneziani I, Culicetto L, Quartarone A, Lo Buono V. Journal of Clinical Medicine. 2024.
12. Disentangling Suicidal Ideation From Behaviour in Huntington's Disease: A Scoping Review of Definitions, Risk Factors, and Research Gaps. — Stone F, Gathii E, Stewart I. General Hospital Psychiatry. 2026.
13. No Going Home for Hospitalized Huntington's Disease Patients. — Dubinsky RM. Movement Disorders : Official Journal of the Movement Disorder Society. 2005.
14. Characterization of Psychiatric Admissions in Huntington Disease: A Retrospective Review. — Shiino S, Moroz S, Stovall J, et al. Journal of Psychosomatic Research. 2025.
15. FDA Orange Book. — FDA Orange Book. 2026.
16. Safety and Efficacy of VMAT2 Inhibitors in Huntington Disease: A Systematic Review. — Baghaei A, Dehnavi AZ, Hashempour Z, et al. Parkinsonism & Related Disorders. 2026.
17. Comparison of Tetrabenazine, Tiapride and Olanzapine in Huntington's Disease: A One-Year French Randomized Multicenter Study (Neuro-Hd). — Youssov K, Audureau E, Pariente J, et al. Parkinsonism & Related Disorders. 2025.
18. Psychosis in Huntington's Disease: A Systematic Review of Case Reports. — Yakubu AO, Olalude OE, Anifalaje OK, et al. General Hospital Psychiatry. 2025.
19. Changes in Mental State and Behaviour in Huntington's Disease. — Eddy CM, Parkinson EG, Rickards HE. The Lancet. Psychiatry. 2016.
20. Dysphagia, Fear of Choking and Preventive Measures in Patients With Huntington's Disease: The Perspectives of Patients and Caregivers in Long-Term Care. — Kalkers K, Schols JMGA, van Zwet EW, Roos RAC. The Journal of Nutrition, Health & Aging. 2022.
21. Predictors of Malnutrition Risk in Neurodegenerative Diseases: The Role of Swallowing Function. — Pizzorni N, Ciammola A, Casazza G, et al. European Journal of Neurology. 2022.
22. Huntington's Disease. — Walker FO. Lancet. 2007.
23. Clinical Correlates of Depression and Suicidality in Huntington Disease: An Analysis of the Enroll-Hd Observational Study. — Rocha NP, Tuazon MR, Patino J, Furr Stimming E, Teixeira AL. Cognitive and Behavioral Neurology : Official Journal of the Society for Behavioral and Cognitive Neurology. 2022.
24. Risk Factors for Suicidality in Huntington Disease: An Analysis of the 2CARE Clinical Trial. — McGarry A, McDermott MP, Kieburtz K, et al. Neurology. 2019.
25. Dysphagia in Huntington's Disease: Correlation With Clinical Features. — de Tommaso M, Nuzzi A, Dellomonaco AR, et al. European Neurology. 2015.
26. Huntington Disease-Like 2. — Anderson DG, Krause A, Margolis RL GeneReviews® [Internet]. 2025.
27. Advances in Management of Movement Disorders in Children. — Koy A, Lin JP, Sanger TD, et al. The Lancet. Neurology. 2016.
28. Treatment of Hyperkinetic Movement Disorders. — Jankovic J. The Lancet. Neurology. 2009.
29. Non-Huntington's Disease Chorea: An Expanding Universe With Acquired Causes. — Cardoso F, Maia D, Maciel R, et al. Brain : A Journal of Neurology. 2026.
30. Suicidal Ideation and Suicidal Behavior According to the C-SSRS in a European Cohort of Huntington's Disease Gene Expansion Carriers. — van Duijn E, Vrijmoeth EM, Giltay EJ, Bernhard Landwehrmeyer G. Journal of Affective Disorders. 2018.
31. Evidence-Based Guideline: Pharmacologic Treatment of Chorea in Huntington Disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology. — Armstrong MJ, Miyasaki JM. Neurology. 2012.
32. Management and Treatment for Dysphagia in Neurodegenerative Disorders. — Ueha R, Cotaoco C, Kondo K, Yamasoba T. Journal of Clinical Medicine. 2023.
33. Huntington disease. — National Library of Medicine (MedlinePlus) 2020.
34. Clinical Policy: Critical Issues in the Diagnosis And Management of the Adult Psychiatric Patient In the Emergency Department. — Nazarian DJ, Broder JS, Thiessen MEW, et al. Annals of Emergency Medicine. 2017.
35. Intramuscular Midazolam, Olanzapine, Ziprasidone, or Haloperidol for Treating Acute Agitation in the Emergency Department. — Klein LR, Driver BE, Miner JR, et al. Annals of Emergency Medicine. 2018.